H-Index
34
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
call: +1.631.629.4327
Mon-Fri 10 am - 2 pm EST

Logo

MSMbanner
Medical Science Monitor Basic Research

AmJCaseRep
MedSciTechnol

eISSN: 2329-0358

Possibility to Treat Lung Tuberculosis without Use of Rifampicin in Heart Transplant Recipients – Two Cases Report

Dariusz Jastrzebski, Michal Zakliczynski, Jerzy Kozielski, Miroslawa Siola, Szymon Dworniczak, Agnieszka Wojdyla, Marian Zembala

Ann Transplant 2003; 8(1): 42-44

ID: 496881

Available online:

Published: 2003-03-14


Pulmonary infections remain the leading cause of death in patients after heart transplantation. Lung tuberculosis is more common in transplant recipients than in general population. Two cases of tuberculosis are presented in patients after heart transplantation. Regarding to influence of rifampicin on immunosuppressive therapy, those patients were treated with antimycobacterial drugs except rifampicin. A cure without recurrence can be achieved with a scheme of treatment regimes without rifampicin.

Keywords: Heart Transplantation, Lung Tuberculosis Treatment



Back